Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Elizabeth Fox, MD, MS

Elizabeth Fox, MD, MS

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Division of Oncology
CTRB4016
3501 Civic Center Blvd
Philadelphia, PA 19104
Education:
BS (Laboratory Sciences)
Northeastern University, College of Pharmacy & Allied Health, Boston, MA, 1988.
MD
Pennsylvania State University College of Medicine Hershey, PA, 1993.
MS (Clinical Research)
Duke University College of Medicine Durham, NC, 2006.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Zur K, Fox E: Chemotherapy for Management of Pulmonary & Laryngotracheal Papillomatosis in a Child. Laryngoscope 127(7): 1538-1542, July 2017.

Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL Liu X, Minard CG, Fox E, Weigel BJ, Blaney S.: Pediatric phase 1 trial and pharmacokinetic study of trebananib in relapsed solid tumors ADVl1115: A Children's Oncology Group phase 1 consortium report. Clin Cancer Res Page: doi: 10.1158/1078-0432.CCR-16-2882. Jul 2017.

Rheingold S, Tasian SJ, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, and Blaney SM: A Phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study (ADVL1114) Br J Hematology 177(3): 467-474, May 2017.

Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E: Dosing Anticancer Drugs in Infants: Current Approach and Recommendations from the Children’s Oncology Group’s Chemotherapy Standardization Task Force Pediatric Blood and Cancer DOI: 10.1002/pbc.26636, May 2017.

Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. : Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors (ADVL1111): A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial. Ped Blood Cancer DOI: 10.1002/pbc.26565, April 2017.

Balis FM, Thompson PA, Mosse YP, Blaney SB, Minard CG, Weigel BJ, Fox E: First Dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1 Consortium. Cancer Chemotherapy Pharmacol 79(1): 181-187, Jan 2017.

Cole KA, Reid JM, Liu X, Minard CG, Maris JM, Fox E, Weigel, BJ: Pediatric phase I trial of the WEE1 inhibitor AZD1775 and irinotecan in patients with refractory solid and CNS malignancies; A Children’s Oncology Group Study (ADVL1312). American Association for Cancer Research, Annual Meeting, Washington, DC 2017 Notes: Poster.

Davis KL, Fox E, Reid JM, Liu X, Minard CG, Weigel B, Mackall CL: ADVL1412: Initial Results of A Phase I/II Study of Nivolumab ± Ipilimumab in Pediatric Patients with Relapsed/Refractory Solid Tumors-A Children’s Oncology Group Study. American Society of Clinical Oncology, Chicago, IL 2017 Notes: Poster.

Levin K, Fox E, Zhu J, DeBernardo A, Gottschalk J, Segers B, Balis FM: Cisplatin ototoxicty in patients with osteosarcoma treated with and without the organic cation transporter 2 inhibitor pantoprazole. American Society of Pediatric Hematology and Oncology, Annual Meeting, Montreal Canada 2017 Notes: Poster.

Desai A, Brodeur G, Foster J, Shusterman S, Sabnis S, Macy M, Wetmore C, Basu E, Hornby Z, Esquibel V, Maneval EC, Multani P, Fox E: STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions. American Association for Cancer Research, Annual Meeting, Washington, DC 2017 Notes: Poster.

back to top
Last updated: 09/07/2017
The Trustees of the University of Pennsylvania